A Key Role for the Urokinase Plasminogen Activator (uPA) in Invasive Group A Streptococcal Infection

PLoS Pathogens

Volumn 9, Issue 7, 2013, Pages

  Sanderson Smith, Martina L ^a   Zhang, Yueling ^b   Ly, Diane ^a   Donahue, Deborah ^b   Hollands, Andrew ^c   Nizet, Victor ^c   Ranson, Marie ^a   Ploplis, Victoria A ^b   Walker, Mark J ^d   Castellino, Francis J ^b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID; PLASMIN; PLASMINOGEN; STREPTOKINASE; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CHEMOLUMINESCENCE; COLONY FORMING UNIT; CONTROLLED STUDY; GROUP A STREPTOCOCCAL INFECTION; HOMOLOGOUS RECOMBINATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84884744333     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003469     Document Type: Article

References (35)

1. Sanderson-Smith M, De Oliveira DP, Ranson M, McArthur JD, (2012) Bacterial plasminogen receptors: Mediators of a multifaceted relationship. Journal of Biomedicine and Biotechnology 2012doi: 10.1155/2012/272148.
2. McArthur JD, Cook SM, Venturini C, Walker MJ, (2012) The role of streptokinase as a virulence determinant of Streptococcus pyogenes-potential for therapeutic targeting. Curr Drug Targets 13: 297-307.
3. Sun H, Xu Y, Sitkiewicz I, Ma Y, Wang X, et al. (2012) Inhibitor of streptokinase gene expression improves survival after group A streptococcus infection in mice. Proc Natl Acad Sci U S A 109: 3469-3474.
4. Sun H, (2011) Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies. J Thromb Haemost 9 Suppl 1: 189-194.
5. Hollands A, Gonzalez D, Leire E, Donald C, Gallo RL, et al. (2012) A bacterial pathogen co-opts host plasmin to resist killing by cathelicidin antimicrobial peptides. J Biol Chem 287: 40891-7.
6. Carapetis JR, Steer AC, Mulholland EK, Weber M, (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5: 685-694.
7. Sanderson-Smith ML, Dinkla K, Cole JN, Cork AJ, Maamary PG, et al. (2008) M protein-mediated plasminogen binding is essential for the virulence of an invasive Streptococcus pyogenes isolate. Faseb J 22: 2715-2722.
8. Cole JN, McArthur JD, McKay FC, Sanderson-Smith ML, Cork AJ, et al. (2006) Trigger for group A streptococcal M1T1 invasive disease. Faseb J 20: 1745-1747.
9. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, et al. (2004) Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 305: 1283-1286.
10. Khil J, Im M, Heath A, Ringdahl U, Mundada L, et al. (2003) Plasminogen enhances virulence of group A streptococci by streptokinase-dependent and streptokinase-independent mechanisms. J Infect Dis 188: 497-505.
11. Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, et al. (2007) DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 13: 981-985.
12. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL, (1995) The cell biology of the plasminogen system. Faseb J 9: 939-945.
13. Wiman B, Collen D, (1978) On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 84: 573-578.
14. Marcum JA, Kline DL, (1983) Species specificity of streptokinase. Comp Biochem Physiol B 75: 389-394.
15. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, et al. (1991) Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem 266: 5147-5152.
16. Orgel D, Schroder W, Hecker-Kia A, Weithmann KU, Kolkenbrock H, et al. (1998) The cleavage of pro-urokinase type plasminogen activator by stromelysin-1. Clin Chem Lab Med 36: 697-702.
17. Croucher DR, Saunders DN, Lobov S, Ranson M, (2008) Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer 8: 535-545.
18. Ellis V, Scully MF, Kakkar VV, (1989) Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 264: 2185-2188.
19. Romer J, Lund LR, Eriksen J, Ralfkiaer E, Zeheb R, et al. (1991) Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol 97: 803-811.
20. Beyrich C, Loffler J, Kobsar A, Speer CP, Kneitz S, et al. (2011) Infection of human coronary artery endothelial cells by group B streptococcus contributes to dysregulation of apoptosis, hemostasis, and innate immune responses. Mediators Inflamm 2011: 971502.
21. Winkler F, Kastenbauer S, Koedel U, Pfister HW, (2002) Role of the urokinase plasminogen activator system in patients with bacterial meningitis. Neurology 59: 1350-1355.
22. Aziz RK, Kotb M, (2008) Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg Infect Dis 14: 1511-1517.
23. Ellis V, Scully MF, Kakkar VV, (1987) Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study. J Biol Chem 262: 14998-15003.
24. Husain SS, (1991) Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. Biochemistry 30: 5797-5805.
25. Stillfried GE, Saunders DN, Ranson M, (2007) Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res 9: R14.
26. Lottenberg R, Broder CC, Boyle MD, (1987) Identification of a specific receptor for plasmin on a group A streptococcus. Infect Immun 55: 1914-1918.
27. Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Romer J, et al. (1996) Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A 93: 5899-5904.
28. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, et al. (1994) Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424.
29. Jogi A, Rono B, Lund IK, Nielsen BS, Ploug M, et al. (2010) Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice. PLoS One 5: e12746.
30. Grondahl-Hansen J, Agerlin N, Munkholm-Larsen P, Bach F, Nielsen LS, et al. (1988) Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 111: 42-51.
31. Plesner T, Ploug M, Ellis V, Ronne E, Hoyer-Hansen G, et al. (1994) The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 83: 808-815.
32. Rijken DC, Lijnen HR, (2009) New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 7: 4-13.
33. Baldi A, Pecorini C, Rebucci R, Saccone F, Cheli F, et al. (2012) Effect of Escherichia coli lipopolysaccharide on u-PA activity and u-PA and u-PAR RNA expression in a bovine mammary epithelial cell line. Res Vet Sci 93: 758-762.
34. Ashbaugh CD, Wessels MR, (2001) Absence of a cysteine protease effect on bacterial virulence in two murine models of human invasive group A streptococcal infection. Infect Immun 69: 6683-6688.
35. Zimmerman M, Quigley JP, Ashe B, Dorn C, Goldfarb R, et al. (1978) Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells: kinetics and inhibitor profiles. Proc Natl Acad Sci U S A 75: 750-753.